Supernus Pharmaceuticals
Manufacturing · Maryland, United States · 501-1,000 Employees
View Company Info for Free
Overview
Headquarters
9715 Key West Ave, Rockville, Maryland, ...Phone Number
(301) 838-2500Website
www.supernus.comRevenue
$776.8 MillionStock Symbol
SUPNIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
5
5
1
2
1
1
About Supernus Pharmaceuticals
Founded in 2005 and headquartered in Rockville, Maryland, Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases.Explore more
Supernus Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Supernus Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Supernus Pharmaceuticals is spiking on competitors!
Check if Supernus Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Click to see if Supernus Pharmaceuticals had a recent Job posting/layoffs
Product Launch: Get notified when Supernus Pharmaceuticals launches new products
Congratulate Masked Content for being promoted to Masked Content at Supernus Pharmaceuticals
Earning: See what the market has to say on Supernus Pharmaceuticals recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Supernus Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Supernus Pharmaceuticals has new funding data
Website visits: Recent activity has been detected on your website
Recommended Actions
Find VP level buyers at Supernus Pharmaceuticals
Find 3 more new buyers
Compare Similar Companies to Supernus Pharmaceuticals
Compare insights from companies similar to Supernus Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Supernus Pharmaceuticals
$776.8M
501-1,000
Public
$80M
2005
JK
Jack KhattarPresident and CEO, Supernus Pharmaceuticals, Inc
Company Profile Activity
Activity Insights
Supernus Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Supernus Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Supernus Pharmaceuticals.
Supernus Pharmaceuticals financials insights
Gather financial insights about Supernus Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2011
Debt
$30M
2012
Stock Offering
$50M
Supernus Pharmaceuticals Tech Stack
A closer look at the technologies used by Supernus Pharmaceuticals
Most Recent Scoops
Open Position
Open Position
Open Position
Open Position
Open Position
Supernus Pharmaceuticals News & Media
What to Know About This Fund’s Sale of a Pharma Stock Up 56% in a Year
Supernus Pharmaceuticals delivers specialty therapies for CNS disorders, targeting healthcare providers and specialty pharmacies nationwide.Supernus Pharmaceuticals to Participate in the Bank of America 2026 Health Care Conference
ROCKVILLE, Md., May 06, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack A. Khattar, President and CEO of Supernus Pharmaceuticals, will participate in a fireside chat at the Bank of America 2026 Health Care Conference on Tuesday, May 12, 2026, at 3:40 p.m. PT (6:40 p.m. ET) at the Encore Hotel inSupernus Announces First Quarter 2026 Financial Results
ROCKVILLE, Md., May 05, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced financial results for the first quarter 2026 and associated Company developments.Supernus Pharmaceuticals to Announce First Quarter 2026 Financial Results and Host Conference Call on May 5, 2026
ROCKVILLE, Md., April 22, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that it will report first quarter 2026 financial and business results after the market closes on Tuesday, May 5, 2026.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Supernus Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Founded in 2005 and headquartered in Rockville, Maryland, Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases.... Read More
